

Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

Atty. Docket No. A34585-A PCT-USA  
(070050.1739)

Serial No. 09/937,165

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant(s): Fisher *et al.*

Filed: July 26, 2002

Group Art Unit  
1632

## U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
48	48. 2 0 0 1 0 0 4 9 1 2 0	12/6/01	Fisher et al.			
54	54. 5 6 5 4 1 6 8	8/5/97	Bujard et al.	435	69.1	

## FOREIGN PATENT DOCUMENT

	Document No.	Date	Country	Class	SubClass	Translator Yes No
50	0 0 2 8 0 6 2	5/18/00	WO			
51	0 0 5 5 3 1 0	9/21/00	WO			

## OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

47.	Beckton Dickinson Biosciences eCatalog, 2003, Tet-On™ and Tet-Off™ Gene Expression System
49.	Akagi Ket al. (2001) A novel tetracycline-dependent transactivator with E2F4 transcriptional activation domain. Nucleic Acids Res 29(4):E23.
52.	Strathdee et al., (1999) Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector. Gene. 229(1-2):21-9.
53.	Rose et al (1997) Integration of tetracycline regulation into a cell-specific transcriptional enhancer J Biol Chem 8(21): 4735-4739.
55.	Qin et al (1997) Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression Human Gene Therapy 8: 2019-2029.
56.	Goldman LA, Cutrone EC, Kotenko SV, Krause CD, Langer JA. Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. BioTechniques 1996;21:1013-1015.

NY02:525076.1

Examiner

Shin-Lin Chen

Date Considered

8-16-05

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.